Stock sales from drug developers are off to a flying start on US exchanges in 2026, boosting the prospects for biotechnology ...

Legend Biotech Corporation (NASDAQ:LEGN) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts.

On the last trading day of 2025, Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

Theratechnologies’ R&D staff is bearing the brunt of its commercial failings. With sales falling short of expectations, the biotech is reducing its R&D head count and narrowing its focus to lower ...

July 25 (Reuters) - Danaher Corp (DHR.N), opens new tab on Tuesday cut its annual sales growth forecast for a second straight quarter, signaling that funding crunch in the drug development market was ...

Specialty drugs surpass pharma sales, reaching 52% of U.S. pharmaceutical sales in 2024, driven by immunology and oncology therapies.

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our full ...